Blavin Fredric, Waidmann Timothy, Blumberg Linda J, Roth Jeremy
The Urban Institute, Washington, DC, USA
The Urban Institute, Washington, DC, USA.
Med Care Res Rev. 2014 Aug;71(4):416-32. doi: 10.1177/1077558714533820. Epub 2014 May 14.
Over the past decade, prescription drug expenditures grew faster than any other service category and comprised an increasing share of per capita health spending. Using the 2005 and 2009 Medical Expenditure Panel Surveys, this analysis identifies the sources of spending growth for prescription drugs among the nonelderly population. We find that prescription drug expenditures among the nonelderly increased by $14.9 billion (9.2%) from 2005 to 2009 and expenditures increased in 12 out of the 16 therapeutic classes. Changes in the number of users and expenditures per fill were the drivers of spending fluctuations in these categories. The main results also provide insight into generic entry, the price gap between brand and generic drugs, and from a health reform evaluation perspective, the importance of separating prepolicy secular trends in expenditures from changes attributable to specific forces, such as shifts toward generic versions of blockbuster drugs.
在过去十年中,处方药支出的增长速度超过了任何其他服务类别,并且在人均医疗支出中所占份额不断增加。利用2005年和2009年医疗支出小组调查,本分析确定了非老年人群体中处方药支出增长的来源。我们发现,非老年人群体的处方药支出在2005年至2009年间增加了149亿美元(9.2%),16个治疗类别中有12个类别的支出有所增加。用户数量的变化和每次配药的支出是这些类别的支出波动的驱动因素。主要结果还提供了对仿制药进入、品牌药与仿制药之间的价格差距的洞察,并且从医疗改革评估的角度来看,将政策前支出的长期趋势与特定因素(如转向畅销药的仿制药版本)导致的变化区分开来的重要性。